ReviewJournal of the advanced practitioner in oncology
Hypercalcemia of Malignancy.
Review in Journal of the advanced practitioner in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Treatment of hypercalcaemia of malignancy in adults.Clinical medicine (London, England) · 2023Pooled it
- PTHrP-associated hypercalcemia in gynecologic malignancies: a scoping review.Archives of gynecology and obstetrics · 2026Article
- Structure-Encoded Location Biased Signaling in a Class B GPCR: Focus on the PTH Type 1 Receptor.Handbook of experimental pharmacology · 2026Review
- Peritoneal Mesothelioma Diagnosed on Frozen Section During Diagnostic Laparoscopy: A Case Report.Cureus · 2025Article
- Highly efficient NIR-II photothermal therapy amplified ROS oxide breast tumor therapy by mesoporous gallium-enriched platinum nanomedicine.Materials today. Bio · 2025Article
- Dual-mediated PTH and Osteolytic Hypercalcemia in Metastatic Endometrial Carcinoma.JCEM case reports · 2025Article
- Endocrine paraneoplastic syndromes in lung cancer: A call for clinical vigilance (Review).Molecular and clinical oncology · 2025Review
- Targeting PAR-2-driven inflammatory pathways in colorectal cancer: mechanistic insights from atorvastatin and rosuvastatin treatment in cell line models.Translational cancer research · 2025Article
- [Severe hypercalcemia in intensive care medicine].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2025Review
- An Overview of the Management of Electrolyte Emergencies and Imbalances in Cancer Patients.Journal of the advanced practitioner in oncology · 2025Review
- Esophageal Adenocarcinoma Presenting With Hypercalcemia.ACG case reports journal · 2025Article
- Review
- Acute pancreatitis related to hypercalcemia as initial manifestation of cancer: About 4 cases.Radiology case reports · 2024Article
- Survival Outcomes in Malignancy-related Hypercalcemia: A Tertiary Care Single-center Experience.Journal of cancer & allied specialties · 2024Article
- Catch the Calcium: T-Cell Histiocyte-Rich B-Cell Lymphoma Presenting as Hypercalcemia.World journal of oncology · 2023Article
- Giant Mandibular Ameloblastoma with Rare Hypercalcemia: A Case Report and Literature Review.Medicina (Kaunas, Lithuania) · 2023Review
- Efficacy assessment of methylcellulose-based thermoresponsive hydrogels loaded with gallium acetylacetonate in osteoclastic bone resorption.Drug delivery and translational research · 2023Article
- Molecular Mechanisms of PTH/PTHrP Class B GPCR Signaling and Pharmacological Implications.Endocrine reviews · 2023Article
- Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.Journal of bone oncology · 2022Review
- Seizures Associated With Bone Density Conservation Agents.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypercalcemia of malignancy (HCM) is a common concern in patients being treated for cancer, affecting over a quarter of this population. There are multiple causes of HCM, including humoral HCM, osteolytic HCM, ectopic hyperparathyroidism, and vitamin D-secreting lymphomas. Common signs and symptoms of HCM can range from mild gastrointestinal disturbances and fatigue to seizures, coma, or even cardiac arrest depending on the severity of the laboratory abnormality. Treatment has evolved in recent years and varies based on the underlying cause of the HCM. Management options include aggressive hydration, bisphosphonates, denosumab, calcitonin, and corticosteroids. It is imperative that advanced practitioners understand the pathophysiology behind the HCM so that proper treatment can be chosen. Early and appropriate treatment is key to successful outcomes. It is also important for continuous monitoring to occur alongside treatment for HCM to prevent potential adverse effects. Finally, the ultimate resolution of HCM comes only from the treatment of the underlying malignancy; therefore, all previously undiagnosed patients should be referred to an oncologist early after HCM is recognized.
Identifiers
31086686PMC6505545What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.